A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats
A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats
复制标题
DOI：
10.1016/j.vaccine.2004.06.049
复制
发表时间：
2004-12-21
期刊：
影响因子：
5.5
通讯作者：
Sullivan, VJ
中科院分区：
文献类型：
--
作者：
Huang, J;Garmise, RJ;Sullivan, VJ
鼻内（IN）疫苗接种代表了一种有吸引力的非侵入性替代针基注射，并在粘膜表面提供优越的保护。然而，需要新的配方来提高效力并减少与标准液体疫苗相关的冷藏储存和分发要求。在这里，我们描述了一种全灭活流感病毒的粉末配方和一种新的注射平台。粉末配方疫苗在大鼠中引起了显著的血清抗体反应，其强度至少与静脉注射或肌内注射的液体疫苗一样强。仅在给药后也观察到显著的鼻腔IgA反应。这项研究首次证明了使用IN递送的流感疫苗粉末可产生有效的鼻黏膜和全身免疫反应，并提出了一种替代流感和其他传染病疫苗接种的方法。(C) 2004 Elsevier Ltd.版权所有。
Intranasal (IN) vaccination represents an attractive non-invasive alternative to needle-based injection and provides superior protection at mucosal surfaces. However, new formulations are needed to improve efficacy and reduce the refrigerated storage and distribution requirements associated with standard liquid vaccines. Here, we describe a powder formulation of whole inactivated influenza virus and a novel IN delivery platform. The powder-formulated vaccine elicited a significant serum antibody response in rats that was at least as strong as that provided by the liquid vaccine administered IN or via intramuscular (IM) injection. Significant nasal IgA responses were also observed solely after IN delivery. This study demonstrates for the first time the generation of potent nasal mucosal and systemic immune responses using an IN delivered influenza vaccine powder and suggests an alternative approach to vaccination against influenza and other infectious diseases. (C) 2004 Elsevier Ltd. All rights reserved.